Document Detail

Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter.
MedLine Citation:
PMID:  17043154     Owner:  NLM     Status:  MEDLINE    
Serum uric acid (SUA) is currently recognized as a risk factor for cardiovascular disease. It has been reported that an angiotensin II receptor blocker (ARB), losartan, decreases SUA level, whereas other ARBs, such as candesartan, have no lowering effect. Because the renal uric acid transporter (URAT1) is an important factor controlling the SUA level, we examined the involvement of URAT1 in those differential effects of various ARBs on SUA level at clinically relevant concentrations. This study was done by using URAT1-expressing Xenopus oocytes. Losartan, pratosartan, and telmisartan exhibited cis-inhibitory effects on the uptake of uric acid by URAT1, whereas at higher concentrations, only telmisartan did, and these ARBs reduced the uptake in competitive inhibition kinetics. On the other hand, candesartan, EXP3174 [2-n-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yI)methyl]imidazole-5-carboxylic acid] (a major metabolite of losartan), olmesartan, and valsartan were not inhibitory. Preloading of those ARBs in the oocytes enhanced the URAT1-mediated uric acid uptake, showing a trans-stimulatory effect. The present study is a first demonstration of the differential effects of ARBs on URAT1 that some ARBs are both cis-inhibitory and trans-stimulatory, depending on concentration, whereas others exhibit either a trans-stimulatory or cis-inhibitory effect alone, which could explain the clinically observed differential effects of ARBs on SUA level. Furthermore, it was found that such differential effects of ARBs on URAT1 could be predicted from the partial chemical structures of ARBs, which will be useful information for the appropriate use and development of ARBs without an increase of SUA.
Takashi Iwanaga; Masanobu Sato; Tomoji Maeda; Toshio Ogihara; Ikumi Tamai
Related Documents :
7235904 - Urinary in vitro sedimentation: effects of nondialyzable components and heparin.
2214614 - Acute uric acid nephropathy in two gouty patients with moderate hyperuricemia and high ...
16263504 - Associations of uric acid with polymorphisms in the delta-aminolevulinic acid dehydrata...
17571264 - Hypouricemic effect and regulatory effects on autonomic function of shao-yao gan-cao ta...
24167374 - Serum paraoxonase 1 activity is associated with fatty acid composition of high density ...
6704454 - Developmental changes in mitochondrial components in liver of newborn rats.
Publication Detail:
Type:  Journal Article     Date:  2006-10-16
Journal Detail:
Title:  The Journal of pharmacology and experimental therapeutics     Volume:  320     ISSN:  0022-3565     ISO Abbreviation:  J. Pharmacol. Exp. Ther.     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2006-12-21     Completed Date:  2007-02-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376362     Medline TA:  J Pharmacol Exp Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  211-7     Citation Subset:  IM    
Department of Molecular Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamasaki, Noda, Chiba 278-8510, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II Type 1 Receptor Blockers / blood,  pharmacology*
Dose-Response Relationship, Drug
Imidazoles / pharmacology
Losartan / pharmacology
Organic Anion Transporters / physiology*
Organic Cation Transport Proteins / physiology*
Pyrazinamide / analogs & derivatives,  pharmacology
Tetrazoles / pharmacology
Uric Acid / metabolism
Valine / analogs & derivatives,  pharmacology
Xenopus laevis
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Imidazoles; 0/Organic Anion Transporters; 0/Organic Cation Transport Proteins; 0/SLC22A12 protein, human; 0/Tetrazoles; 0/olmesartan; 114798-26-4/Losartan; 137862-53-4/valsartan; 69-93-2/Uric Acid; 7004-03-7/Valine; 98-96-4/Pyrazinamide; 98-97-5/pyrazinoic acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Positive charges at the intracellular mouth of the pore regulate anion conduction in the CFTR chlori...
Next Document:  Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a nu...